Alteration in gut microbiota or "dysbiosis" has been demonstrated in several chronic diseases, including chronic liver disease and cirrhosis. This dysbiosis is characterized by alteration in the Bacteroides/Firmicutes ratio and increase in potentially pathogenic taxa such as *Enterobacteriaceae* in diseased states.[@R1]^,^[@R2] In cirrhosis, these changes have been associated with complications such as hepatic encephalopathy (HE).[@R1] Therefore an understanding of the multiple factors that influence these changes in gut microbiota may increase insight into the progression of liver disease. One critical component of the intestinal milieu are bile acids which have downstream effects on processes as varied as GI motility, nutrition, carcinogenesis and intestinal permeability. A picture is emerging in which the bile acid pool size and composition modulates the size and composition of the gut microbiome and vice versa.

The study of the interaction between bile acids and gut microbiota in the context of liver disease is essential because the human liver is the only organ in the body that produces all 14 enzymes required for de novo synthesis of the primary bile acids.[@R3] The "classical" or "neutral" pathway of bile acid synthesis begins with cholesterol 7α-hydroxylase (CYP7A1), which produces both the dihydroxy bile acid chenodeoxycholic acid (CDCA; 3α, 7α) and the trihydroxy bile acid cholic acid (CA; 3α, 7α, 12α). The "acidic" pathway produces mostly CDCA and is initiated by mitochondrial sterol 27 hydroxylase (CYP27A1) catalyzed side-chain oxidation, which is followed by cleavage of a three-carbon side chain resulting in the C-24 bile acids. CA synthesis requires sterol 12α-hydroxylase (CYP8B1) followed by side-chain oxidation and cleavage.[@R4] The classical pathway produces the majority of the two primary bile acids in healthy humans. In the diseased liver, the classical pathway is down-regulated and the acidic pathway produces most of the primary bile acids.[@R5] Bile acids are conjugated to glycine or taurine before being secreted from the liver and stored in the gallbladder. Eating stimulates gallbladder contraction and emptying of the contents into the small intestine. Bile salts function to solubilize fats and fat-soluble vitamins before they are actively transported across the ileum, entering the portal circulation, and return to the liver in what is termed the entero-hepatic circulation (EHC). The EHC is 95% efficient, with roughly 600--800 mg bile salts escaping into the large bowel daily.[@R6]

The large bowel is the most densely populated natural environment known, containing roughly 10^14^ bacterial cells.[@R7] Diversity in this environment is almost entirely at lower taxonomic levels (genus, species, strain).[@R8] Phylum level diversity in the gut is remarkably low, with two major divisions, the Bacteroidetes and Firmicutes predominating, followed by Actinoacteria. Greater than 99% of the functional genes associated with the human body are microbial, and most of these are found in bacteria colonizing the large bowel.[@R9] The lumen of the large bowel is a highly anaerobic environment and microbes that occupy this ecological niche must carry out fermentative metabolism in order to generate ATP and grow. The main endogenous substrate used by the large bowel microbiota consists of sloughed intestinal epithelial cells (100--200 g/day) and bile components, whereas, exogenous substrates include resistant starch, plant polysaccharides and proteins. From these substrates gut bacteria produce mostly short chain fatty acids (acetate, propionate and butyrate). During EHC bile acids enter the colon where they are metabolized by the large bowel microbiota. CA and CDCA are 7α-dehydroxylated exclusively by a small population of anaerobic bacteria to form deoxycholic acid (DCA) and lithocholic acid (LCA), respectively.[@R10] Human gut bacteria carrying out bile acid 7α-dehydroxylation have been shown to belong to the genus *Clostridium*, which are gram-positive anaerobic spore forming members of the Firmicutes.[@R11]^-^[@R13]

Animal model studies demonstrate that increased bile acid levels in the colon select against the Bacteroidetes and Actinobacteria and favor the Firmicutes including bile acid 7α-dehydroxylating bacteria in vivo.[@R14] Indeed, Islam et al. (2011) reported a marked increase in Firmicutes (control 54%; CA feeding 95%) with greatest increase in members of clostridial cluster XIVa following CA feeding in rats and significant increase in DCA with higher input of CA.[@R14] We have detected bile acid 7α-dehydroxylation activity in *Clostridium scindens, C. hiranonis, C. hylemonae* and *C. sordellii*, which are each nested within a phylogenetic tree containing members of *Blautia, Ruminococcaceae* and *Lachnospiraceae* all of which are in clostridial rRNA cluster XIVa ([Fig. 1](#F1){ref-type="fig"}). We have determined the levels of bile acid 7α-dehydroxylating bacteria in control C57BL/6 mice fed a normal chow diet (NC) and in mice fed a NC diet plus 1% w/w cholic acid. After 2 weeks of feeding, the ceca were removed and immediately serially diluted in anaerobic brain heart infusion broth containing \[24-^14^C\]-cholic acid. We observed a 1000-fold increase in the levels of bile acid 7α-dehydroxylating bacteria (p = 0.001) with cholic acid feeding consistent with the hypothesis that increased primary bile acid substrate supports a larger population of these bacteria in the intestines ([Fig. 2](#F2){ref-type="fig"}).

![**Figure 1.** Reference species tree of the clostridia and related *Clostridiales* bacteria. Phylogenetic tree obtained from analysis. Maximum likelihood and Bayesian analyses of 20 concatenates single-copy proteins from 99 genomes, showing showing *Clostridium scindens* as distantly related to most other *Clostridium* species and being deeply embedded in a group of bacteria mainly from the *Lachnospiraceae* and *Ruminococcaceae* families. *Streptococcus sanguinis* SK36 was included as an outgroup. Numbers on nodes indicate support from bootstrap support and posterior probability (numbers below 50 or 0.5 not shown, indicated by a dash); black circles indicate support of 100 and 1, with all other values explicitly written.](gmic-4-382-g1){#F1}

![**Figure 2.** Cholic acid feeding stimulates growth of bile acid 7α-dehydroxylating bacteria in mice. Twelve week old C57Bl/6 mice were fed normal chow (n = 5), or 1% w/w cholic acid (n = 5) for 2 weeks. Cecal contents were then serially diluted (10-fold) in anaerobic brain heart infusion broth containing 10 μM cholic acid and 0.01 μCi \[24-^14^C\] cholic acid. Bile acids were extracted from the medium after 48 h growth, separated by thin layer chromatography (solvent system toluene:dioxane:glacial acetic acid 75:20:2 v:v:v). Semi-quantitative estimates of bile acid 7α-dehydroxylating bacteria were made based on the last dilution tube in which \[24-^14^C\] deoxycholic acid was detected by audoradiography on Kodak Biomax MS film after 48 h exposure. \*p = 0.001, T-test.](gmic-4-382-g2){#F2}

The current publication by Kakiyama et al. (2013) provides interesting data in which dysbiosis is occurring in patients with cirrhosis in part due to low bile acid input into the gut.[@R15] This data suggests that in the absence of bile acids, the bile acid 7α-dehydroxylating bacterial population collapses. Two observations point to this conclusion. First, total bile acids in feces of patients with advanced cirrhosis decreased roughly 5-fold and the ratios of DCA/CA and LCA/CDCA decreased significantly. Second, there is a significant positive correlation between the presence of members of the *Clostridium* cluster XIVa and DCA and LCA concentration. Members of *Clostridium* cluster XIVa, which includes the bile acid 7α-dehydroxylating bacteria, decrease in the intestines as cirrhosis severity advanced. Taken together, these data show a direct relationship between the bile acid pool size and the relative abundance of *Clostridium* cluster XIVa. We have previously elucidated a multi-step bile acid 7α-dehydroxylating pathway in these bacteria that allow them to use primary bile acids as an electron acceptor allowing for increased ATP formation and growth.[@R10]^,^[@R16] However, most members of *Clostridium* cluster XIVa lack the bai operon and thus do not convert CA to DCA, so for most of these microbes, energetic considerations can be ignored. Energetics may be ancillary to production of and resistance to DCA, a potent antimicrobial agent that reduces competition for growth substrates. Is the expansion of the bile acid 7α-dehydroxylating bacteria population due mainly to selection for bile tolerance coupled with reduced competition for growth substrates, or does metabolism of bile acid determine population size of members with the bai operon? We know that growth of these microbes in vitro is not dependent on the presence of bile acids. However, competition for resources in vivo is fierce in the colon, and their low levels (0.0001% of the microbiota) indicate a specialized niche.[@R10] Inhibition of the bile acid 7α-dehydroxylating pathway without inhibition of the organism itself either pharmacologically or through genetic-knockout of the bile acid 7α-dehydroxylating pathway will be necessary to determine the in vivo role of the bile acid 7α-dehydroxylating pathway, particularly in the presence of exogenously added DCA.

At least in rodents, bile acid 7α-dehydroxylating bacteria are capable of regulating bile acid synthesis in the liver by removing an FXR-antagonist, tauro-β-muricholic acid, in the ileum.[@R17] In humans, other members of the microbiome are capable of shrinking the bile acid pool through inhibition of bile acid synthesis in the liver by inflammation.[@R18] As cirrhosis progresses, expression of the ileal bile acid transporter increases, resulting in less bile acids reaching the large bowel, likely due to decreased concentration of bile salts.[@R19] Bacterial overgrowth occurs in the small bowel, often by gram-negative members of the oral and gut microbiota such as *Enterobacteriaceae*, *Veillonellaceae*, *Alcaligeneaceae* and *Porphyromonadaceae*.[@R1]^,^[@R20] Indeed, we have previously shown a positive correlation between levels of *Alcaligeneaceae* and *Porphyromonadaceae* and cognitive impairment in cirrhotic patients who develop hepatic encephalopathy.[@R1] Kakiyama et al. (2013) observed a positive correlation between fecal levels of CDCA and members of the *Enterobacteriaceae*. Previously, Bajaj et al. (2012) found a positive linkage between *Enterobacteriaceae,* endotoxemia and inflammation, which was also positively correlated with development of HE.[@R1]

Lipopolysaccharide (LPS) or endotoxin, a component of the cell wall of gram-negative bacteria varies between species.[@R21] This structural variance leads to differing degrees of inflammation in the host. Quantitatively, species of *Bacteroides* are among the most predominate genera in the human GI tract, while genera within the *Enterobacteriaceae*, *Porphyromonadaceae,* and *Alcaligeneaceae* are only minor members of the gut microbiome of healthy humans, while several members of these families are human pathogens.[@R8] However, LPS from members of the *Enterobacteriaceae*, for instance, show potency on the order of 4--50-fold that of LPS from members of the *Bacteroidetes* in TNF-α assays.[@R22] Indeed, animal models of non-alcoholic fatty liver disease (NAFLD) found a positive correlation between *Porphyromonadaceae* and exacerbation of hepatic steatosis and inflammation through TLR4 and TLR9 activation of TNF-α.[@R23] *Porphyromonas gingivalis* LPS has been shown to induce TNF-α through TLR-2 and TLR-4.[@R24] Therefore, the data presented by Kakiyama et al. (2013) confirm previous observations that increase in specific gram-negative taxa, particularly *Enterobacteriaceae* and *Porphyromonadaceae* could lead to inflammation, which contributes to cirrhosis and its complications. Interestingly, we have previously shown that while the stool microbiome between HE and non-HE cirrhotic patients were not significantly different, the mucosal microbiome differed markedly and toward pathogenic genera in HE.[@R25] Indeed in the current study, and in recently published studies by our group and others, it was shown that rifaximin treatment reduced endotoxemia,[@R26]^,^[@R27] reduced levels of secondary bile acids,[@R15] and reduced harmful metabolites. These metabolites derived from aromatic amino acid metabolism, ammonia metabolism and oxidative stress indicators, which were positively correlated with *Bacteroidaceae, Enterobacteriaceae, Porphyromonadaceae* without significantly altering microbiome community structure.[@R26] Recent studies also suggest that DCA is involved in barrier dysfunction.[@R28]^,^[@R29] While it is unclear if DCA exacerbates barrier dysfunction in cirrhotic patients, our observation of a combination of reduced DCA/CA ratio, reduction in toxic metabolites from key microbial taxa, improvement in cognitive function and reduction in endotoxemia, warrant further investigation. LCA is likely to play a lesser role due to its insolubility in fecal water. Indeed, fecal levels of LCA increase in early cirrhosis, as bile acid synthesis through the "acidic" pathway is favored; however, LCA was not detected in serum in our study.[@R15]

We hypothesize that a shrinking bile acid pool leads to increases in microbes with potent pro-inflammatory molecules coupled with production of harmful metabolites, which in turn lead to further down-regulation of bile acid synthesis in a positive-feedback mechanism via inflammation. Inhibition of CYP7A1 through inflammation leads to decreased total bile acids[@R18]^,^[@R30] and a shift toward CDCA production through the alternative pathway.[@R3]^,^[@R4] This explains the current observation of 1) decreased total bile acid synthesis, 2) CDCA synthesis predominating over CA. As the input of CA into the colon decreases so do the levels of DCA. DCA is by far the most potent antimicrobial among bile acids.[@R31] Key changes in the microbiome may thus serve as a marker for changes in the bile acid pool composition and vice versa. [Figure 3](#F3){ref-type="fig"} summarizes a model that may explain the relationship between bile acids, key elements in the microbiome and cirrhosis.

![**Figure 3.** A model for the relationship between bile acids, the microbiome and cirrhosis. In healthy individuals, cholesterol is primarily converted to CA and CDCA by the neutral bile acid biosynthetic pathway. Sufficient quantities of bile salts enter the small intestine to prevent dysbiosis and the release of inflammatory markers (i.e., LPS). Bile acid 7α-dehydroxylating bacteria are found in normal range (10^3^--10^5^ cells per gram wet weight), and the ratio of secondary to primary bile acids in stool is high. In cirrhosis, the neutral pathway is repressed due to downregulation of CYP7A1 by proinflammatory cytokines, and the acidic pathway is the primary pathway for bile acid synthesis. Dysbiosis occurs due to lower concentration of bile salts entering the small bowel. This dybiosis is characterized by inflammation due to an increase in organisms with potent LPS such as members of the *Enterobacteriaceae.* The population of 7α-dehydroxylating bacteria in the colon is hypothesized to decrease due to lower levels of primary bile acids which are thought to serve the as an energy source. Consequently, ratio of secondary/primary bile acids is low in cirrhosis.](gmic-4-382-g3){#F3}

The study of secondary BA formation as a potential marker for disease progression in human cirrhosis is important because while the 7α-dehydroxylation can be construed as a "functional test" for microbiota, the production of these secondary BAs does not provide an energy advantage to the human host, but to the bacteria that achieve this conversion. Due to their membrane-destabilizing properties and potential for worsening intestinal permeability, the decrease in secondary BAs in advancing cirrhosis, actually may be protective. This hypothesis is also supported by the reduction in the secondary/primary BA ratio after rifaximin in early cirrhotic patients. Therefore this initial study of BAs in the modulation of the fecal microbiome in worsening cirrhosis raises several important questions that need to be answered in future studies in order to delineate this complex liver-bile acid-microbiome interaction within the gut milieu.
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